The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection
Alberto Signore, Alvaro A. Ordoñez, C. Arjun, Gurpreet Kaur Aulakh, Nicolas Bézière, Ekaterina Dadachova, Thomas Ebenhan, Ulises Granados, Aruna Korde, Amir Reza Jalilian, Wening Lestari, Archana Mukherjee, Miloš Petřík, Tamer M. Sakr, Clara Santos‐Cuevas, Mick M. Welling, Jan Rijn Zeevaart, Sanjay K. Jain, David M. Wilson
Abstract
The International Atomic Energy Agency organized a technical meeting at its headquarters in Vienna, Austria, in 2022 that included 17 experts representing 12 countries, whose research spanned the development and use of radiolabeled agents for imaging infection. The meeting focused largely on bacterial pathogens. The group discussed and evaluated the advantages and disadvantages of several radiopharmaceuticals, as well as the science driving various imaging approaches. The main objective was to understand why few infection-targeted radiotracers are used in clinical practice despite the urgent need to better characterize bacterial infections. This article summarizes the resulting consensus, at least among the included scientists and countries, on the current status of radiopharmaceutical development for infection imaging. Also included are opinions and recommendations regarding current research standards in this area. This and future International Atomic Energy Agency-sponsored collaborations will advance the goal of providing the medical community with innovative, practical tools for the specific image-based diagnosis of infection.